

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Imricor Medical Systems, Inc.
ARBN	633 106 019

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Mark Tibbles
Date of last notice	23 June 2022

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	6 – 10 March 2023

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held prior to change</p>	<ul style="list-style-type: none"> - 4,864,131 shares of Class A common stock and CDIs. - 314,900 options with an exercise price of US\$0.52 per share of Class A common stock and an expiry date of 15 March 2029 - 100,000 options with an exercise price of US\$0.98 (USD equivalent to A\$1.45) per share of Class A common stock and an expiry date of 30 August 2029 - 71,010 options with an exercise price of US\$0.89 (USD equivalent to A\$1.38) per share of Class A common stock and an expiry date of 13 May 2030 (US time). - 40,896 options with an exercise price of US\$1.57 (USD equivalent to A\$2.00) per share of Class A common stock and an expiry date of 7 May 2031 (US time).
<p>Class</p>	<p>CHESSE Depository Interests (CDIs)</p>
<p>Number acquired</p>	<p>574,451</p>
<p>Number disposed</p>	<p>N/A</p>
<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>A\$0.34 per CDI</p>

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

<p>No. of securities held after change</p>	<ul style="list-style-type: none"> - 5,438,582 shares of Class A common stock and CDIs - 314,900 options with an exercise price of US\$0.52 per share of Class A common stock and an expiry date of 15 March 2029 - 100,000 options with an exercise price of US\$0.98 (USD equivalent to A\$1.45) per share of Class A common stock and an expiry date of 30 August 2029 - 71,010 options with an exercise price of US\$0.89 (USD equivalent to A\$1.38) per share of Class A common stock and an expiry date of 13 May 2030 (US time) - 40,896 options with an exercise price of US\$1.57 (USD equivalent to A\$2.00) per share of Class A common stock and an expiry date of 7 May 2031 (US time)
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>On-market trade</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<p>Detail of contract</p>	
<p>Nature of interest</p>	
<p>Name of registered holder (if issued securities)</p>	
<p>Date of change</p>	
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.